Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:33:03.704Z.
Consensus retrieved: 2026-10-06T13:18:41.502Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:33:03.704Z.
Quote observation: 2026-10-06T16:30:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f3e61b787222715dff3a983a87307d60b14e7521dca9159fec0ee57fbd3bd529
Forward PE Ratio (N/A) = Dated Quote Price ($0.84) / Consensus Forward EPS ($4.96)
FORWARD PE RATIO
N/A
Lakewood-Amedex Biotherapeutics, Inc.
Market Cap
$1.48M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Lakewood-Amedex Biotherapeutics, Inc. (LABT) | $1.48M | N/A |
| PMGC Holdings Inc. (ELAB)vs › | $1.48M | N/A |
| Curis, Inc. (CRIS)vs › | $1.50M | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.43M | N/A |
| NEXGEL, Inc. (NXGL)vs › | $1.43M | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | N/A |
| Genprex, Inc. (GNPX)vs › | $1.34M | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.33M | N/A |
| Silo Pharma, Inc. (SILO)vs › | $1.64M | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.20M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.84, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $4.96 | $4.96 – $4.96 | 1 | 0.2x |
| 2027-12-31 | $1.32 | $1.32 – $1.32 | 1 | 0.6x |
| 2028-12-31 | $-1.16 | $-1.16 – $-1.16 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
